Report Description Table of Contents How Are Advanced Screening Technologies, Infectious Disease Testing, and Transfusion Safety Requirements Shaping the Global Blood Screening Market? – (Updated On: 27th-Oct-2026) Blood screening is an essential process for detecting infectious agents in donated blood and ensuring the safety of blood and blood components used in transfusions. It involves nucleic acid testing (NAT), immunoassays, and automated laboratory systems to identify infections such as HIV, hepatitis B, hepatitis C, and syphilis. Strategic Market Research estimates the global Blood Screening Market at USD 3.15 billion in 2025, with revenue projected to reach USD 5.59 billion by 2032, growing at a CAGR of 8.54% during 2026–2032. According to the World Health Organization's June 2026 blood safety update, approximately 120.4 million blood donations are collected worldwide annually, with 36% coming from high-income countries. The WHO also reported that 10 countries were unable to screen every blood donation for certain major infections, highlighting the need for better testing facilities and reliable screening technologies. These findings show how blood collection activity and safety requirements support demand for blood screening products worldwide. New testing technologies are helping blood banks detect more infections while improving testing speed and efficiency. In March 2026, Roche introduced its cobas MPX-E assay, designed to detect HIV, hepatitis B, hepatitis C, and hepatitis E in donated blood through a single molecular screening test. In April 2026, Grifols received FDA approval for its Procleix Plasmodium Assay, which helps identify malaria-causing parasites in donated blood. These developments are creating opportunities for manufacturers of automated blood screening systems, molecular testing kits, and diagnostic reagents as blood banks seek faster, more reliable infection detection and improved transfusion safety. Overall, the Blood Screening Market is increasingly shaped by recurring infectious disease testing, expanding clinical screening applications, and investment in automated diagnostic technologies, creating commercial opportunities for assay manufacturers, laboratory equipment suppliers, and healthcare testing providers. Which Subsegments Are Leading the Blood Screening Market, and Where Are the Fastest-Expanding Opportunities Emerging? By Technology: Nucleic Acid Testing Leads in Revenue and Expansion Leading Subsegment – Nucleic Acid Testing (NAT) Nucleic Acid Testing (NAT) dominates the global Blood Screening Market, accounting for the largest market share of 48%, equivalent to USD 1.512 billion in 2025, and is projected to register the fastest CAGR of 10.50% during 2026–2032. NAT directly identifies viral DNA or RNA in donated blood, enabling earlier detection of transfusion-transmissible infections before antibodies or antigens become detectable. Increasing adoption of molecular screening technologies, expanding blood donation programs, and stringent transfusion safety regulations are strengthening NAT's role in improving blood screening accuracy and reducing infection transmission risks worldwide. By Product and Service: Reagents Lead While Software and Services Expand Fastest Leading Subsegment – Reagents and Consumables Reagents and consumables form the chemical and physical backbone of blood screening procedures, supporting infectious disease detection, blood typing, antibody identification, and molecular diagnostics. Within the global Blood Screening Market, reagents and consumables held the largest share of 66% in 2025, representing a market value of USD 2.079 billion, and are projected to expand at a CAGR of 8.90% during 2026–2032. Their recurring utilization across blood banks, diagnostic laboratories, and hospital transfusion services reinforces sustained procurement of testing kits, assay reagents, and screening materials. Fastest-Growing Subsegment – Software and Services Software and Services accounted for 10% of the global Blood Screening Market, valued at USD 0.315 billion in 2025, and are projected to register the fastest CAGR of 9.43% during 2026–2032. Blood screening software and services provide essential digital infrastructure for laboratory automation, donor information management, diagnostic workflow integration, and regulatory compliance. Increasing adoption of laboratory information management systems, automated test result reporting, and digital blood traceability solutions strengthens operational efficiency, supports accurate donor tracking, reduces screening errors, and improves transfusion safety across blood banks and diagnostic laboratories. By Screening Type: Infectious Disease Screening Maintains Commercial Leadership Leading Subsegment – Infectious Disease Screening Infectious Disease Screening dominates the global Blood Screening Market, accounting for a 56% market share, valued at USD 1.764 billion in 2025, and is projected to register the fastest CAGR of 9.40% during 2026–2032. Its leading position reflects the critical role of infectious disease testing in safeguarding blood transfusions by identifying donated blood containing pathogens or infectious disease markers. Screening for HIV, hepatitis B, hepatitis C, and syphilis supports the early detection of transfusion-transmissible infections, strengthens blood bank safety protocols, and improves patient protection worldwide. By Application: Donor Screening Leads While Clinical Diagnostics Expand Fastest Leading Subsegment – Blood Donor Screening Blood Donor Screening dominated the global Blood Screening Market with a 43% share, valued at USD 1.355 billion in 2025, and is projected to grow at a CAGR of 8.60% during 2026–2032. Blood donor screening serves as the first and most critical safeguard in transfusion safety, protecting recipients from transfusion-transmitted infections while ensuring donor eligibility and well-being. Routine testing for HIV, hepatitis B, hepatitis C, and syphilis, alongside donor health assessments, strengthens blood collection safety and supports reliable blood transfusion services worldwide. Fastest-Growing Subsegment – Clinical Diagnostic Screening Clinical Diagnostic Screening accounted for 33% of the global Blood Screening Market, valued at USD 1.040 billion in 2025, and is projected to register the fastest CAGR of 8.84% during 2026–2032. Clinical diagnostic screening plays a critical role in identifying hidden health risks, detecting diseases before symptoms appear, and supporting blood transfusion safety. Increasing utilization of blood-based diagnostic tests for infectious diseases, chronic conditions, and preventive health assessments is strengthening screening activities across hospitals, diagnostic laboratories, and blood collection centers worldwide. By Sample Type: Whole Blood Leads Across Screening Applications Leading Subsegment – Whole Blood Whole Blood dominates the global Blood Screening Market, accounting for the largest market share of 46%, equivalent to USD 1.449 billion in 2025, and is projected to register the fastest CAGR of 8.80% during 2026–2032. Whole blood plays a crucial role in screening procedures, particularly Complete Blood Count (CBC) and Full Blood Count (FBC) testing, which evaluate red blood cells, white blood cells, platelets, and hemoglobin levels. Its widespread application in routine health examinations, disease detection, and clinical diagnostics supports its leading market position. By End User: Hospitals Lead While Blood Banks Record Faster Expansion Leading Subsegment – Hospitals and Healthcare Institutions Hospitals and healthcare institutions lead the global Blood Screening Market, accounting for a 58% market share, valued at USD 1.827 billion in 2025, with a projected CAGR of 7.97% during 2026–2032. Hospitals function as primary centers for clinical blood collection, diagnostic testing, infectious disease screening, and transfusion safety. High patient volumes, routine preoperative blood testing, emergency transfusion requirements, and stringent blood safety protocols strengthen their market position. Increasing adoption of automated screening platforms and molecular diagnostic technologies further supports screening efficiency and clinical accuracy. Fastest-Growing Subsegment – Blood Banks and Blood Collection Centers Blood Banks and Blood Collection Centers dominated the global Blood Screening Market with a 42% market share, accounting for USD 1.323 billion in 2025, and are projected to register the fastest CAGR of 9.30% during 2026–2032. Blood banks and collection centers conduct pre-donation evaluations, infectious disease screening, blood typing, and compatibility testing to maintain transfusion safety. Increasing blood donation activities, stringent screening regulations, and wider adoption of automated testing platforms are strengthening their role in ensuring a safe and reliable global blood supply. By Geography: North America Leads While Asia-Pacific Offers the Fastest Expansion Leading Region – North America North America dominated the global Blood Screening Market, accounting for the largest market share of 37%, valued at USD 1.166 billion in 2025, and is projected to grow at a CAGR of 7.40% during 2026–2032. The region’s leadership is supported by stringent blood safety regulations, proactive public health initiatives, and widespread adoption of advanced screening technologies. Established healthcare infrastructure, routine screening for transfusion-transmitted infections, and increasing integration of nucleic acid testing (NAT) further strengthen blood screening practices across the United States and Canada. Fastest-Growing Region – Asia-Pacific Asia-Pacific accounted for 25% of the global Blood Screening Market in 2025, representing USD 0.788 billion, and is projected to register the fastest regional CAGR of 11.20% during 2026–2032. Market expansion is supported by government initiatives to strengthen blood transfusion safety, stricter screening regulations, and the increasing prevalence of transfusion-transmissible infections, including HIV, hepatitis B, and hepatitis C. Expanding blood collection infrastructure, growing adoption of nucleic acid testing, and investments in modern diagnostic laboratories across China, India, and Japan further support regional growth. Which Companies Are Leading the Global Blood Screening Market Through Molecular Diagnostics, Immunoassay Technologies, and Laboratory Innovation? Abbott Laboratories – Leading Provider of Automated Blood Screening and Immunoassay Technologies Abbott Laboratories (United States) is a major participant in the global blood screening market, offering automated immunoassay analyzers, molecular diagnostic systems, and infectious disease screening solutions for blood banks and clinical laboratories. Its Alinity s system supports blood and plasma screening for transfusion-transmissible infections, while the Alinity m molecular platform performs nucleic acid testing for infectious diseases. Abbott's ARCHITECT and Alinity i platforms also support serological and clinical diagnostic applications. Abbott reported approximately USD 9.34 billion in Diagnostics segment sales in 2024, reflecting the scale of its broader diagnostic operations rather than blood screening revenue alone. Its competitive positioning is strengthened by automated testing platforms, recurring reagent consumption, and an established international laboratory customer network. Integrated instruments and assay portfolios support long-term procurement relationships with healthcare institutions and blood collection organizations. F. Hoffmann-La Roche Ltd. – Major Supplier of Molecular Blood Screening and Diagnostic Systems F. Hoffmann-La Roche Ltd. (Switzerland) maintains a strong position in blood screening through its cobas molecular diagnostic technologies and automated laboratory systems. Its cobas 6800 and cobas 8800 systems support high-throughput nucleic acid testing, including assays used to identify HIV, hepatitis B, and hepatitis C in donated blood. Roche also provides Elecsys immunoassays and cobas clinical chemistry platforms for infectious disease detection and broader diagnostic screening. Roche's Diagnostics division reported approximately CHF 14.3 billion in sales in 2024, demonstrating the commercial scale of its diagnostic technology portfolio, which extends well beyond blood screening. Its market position benefits from automated molecular testing, extensive assay availability, and integrated diagnostic workflows. The company's blood screening solutions are particularly relevant to centralized laboratories and blood collection organizations requiring standardized testing, reliable performance, and high sample-processing capacity. Other Important Companies in the Blood Screening Market: Quest Diagnostics (United States): Provides clinical blood testing services, including complete blood counts, metabolic assessments, infectious disease diagnostics, and preventive health screening through its laboratory network. Bio-Rad Laboratories, Inc. (United States): Supplies immunohematology instruments, blood grouping reagents, antibody screening systems, and quality-control materials used by blood banks and hospital laboratories. bioMérieux SA (France): Offers VIDAS automated immunoassay systems and infectious disease diagnostic solutions supporting clinical blood sample analysis and laboratory testing workflows. Analyst Commentary: How Will Molecular Testing and Laboratory Integration Advance Blood Screening? The global blood screening market is advancing through wider adoption of nucleic acid testing, automated immunoassays, and high-throughput diagnostic platforms. Increasing emphasis on transfusion safety, early detection of infectious diseases, and accurate blood compatibility testing is strengthening the role of advanced screening technologies. The strongest opportunities lie in multiplex molecular assays, automated donor screening, recurring reagent consumption, and integrated laboratory workflows. Asia-Pacific is emerging as a key expansion region, supported by improving blood collection infrastructure, stricter screening protocols, and increasing investment in molecular diagnostic capabilities. Blood Screening Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 3.15 Billion Revenue Forecast in 2032 USD 5.59 Billion Overall Growth Rate CAGR of 8.54% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Technology, By Product and Service, By Screening Type, By Application, By Sample Type, By End User, By Geography By Technology Nucleic Acid Testing (NAT), Immunoassay Technology, Other Screening Technologies By Product and Service Reagents and Consumables, Instruments and Equipment, Software and Services By Screening Type Infectious Disease Screening, Immunohematology Screening, Other Blood Screening By Application Blood Donor Screening, Transfusion Safety Screening, Clinical Diagnostic Screening By Sample Type Whole Blood, Plasma, Serum By End User Blood Banks and Blood Collection Centers, Hospitals and Healthcare Institutions By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Mandatory infectious disease screening of donated blood, adoption of nucleic acid testing and multiplex assays, recurring reagent consumption, blood collection infrastructure expansion, investment in laboratory automation and transfusion safety Customization Option Available upon request Frequently Asked Question About This Report Q1. What is driving recurring purchases in the market? A1. Every new donation creates a requirement for infection screening, sustaining purchases of assay kits and sample-processing materials. Reagents and consumables account for an estimated 66% share in 2025. Suppliers benefit from repeat testing activity across blood banks and hospital laboratories. Q2. Which innovations are changing the industry’s testing capabilities? A2. Multiplex molecular assays are expanding the number of infections laboratories can screen for within one test. Roche’s cobas MPX-E combines screening for several viruses, while Grifols’ Procleix Plasmodium assay addresses malaria detection. These developments broaden assay portfolios available to blood collection organizations. Q3. Why is molecular testing gaining market share? A3. Nucleic acid testing can identify viral genetic material before some other infection markers become detectable. This capability encourages adoption in donor testing programs. The technology holds an estimated 48% share in 2025 and is projected to grow at a CAGR of 10.50% during 2026–2032. Q4. How are companies strengthening their competitive position in the industry? A4. Suppliers combine automated instruments with broad assay portfolios and ongoing service support. Abbott and Roche use integrated platforms to serve laboratories with substantial testing volumes. Reliable processing and compatibility with laboratory workflows help maintain customer relationships and recurring reagent sales. Q5. Where are the main opportunities for market expansion? A5. Asia-Pacific is projected to record the fastest regional CAGR of 11.20% during 2026–2032. Expanding collection networks and investment in molecular testing create opportunities across China, India and Japan. Suppliers can serve both new laboratory capacity and upgrades to existing testing systems. Q6. What challenges are affecting wider market adoption? A6. Gaps in testing facilities and access to reliable screening technologies limit coverage in some countries. The supplied WHO update identifies 10 countries unable to screen every donation for certain major infections. Expanding coverage requires laboratory investment alongside dependable access to testing supplies. Sources: World Health Organization – Its June 12, 2026 Update Reports 120.4 Million Blood Donations Worldwide, With 36% Collected in High-Income Countries WHO – Blood Safety and Availability: Global Donation Volumes and Screening Requirements World Health Organization – Ten Reporting Countries Could Not Screen All Donations for One or More Major Infections, While 63% of Blood Screening Laboratories Participated in External Quality Assessment WHO – Blood Screening Coverage and Laboratory Quality Assessment U.S. CDC / National Blood Collection and Utilization Survey – Approximately 11.586 Million Whole-Blood and Apheresis Red Blood Cell Units Were Collected in 2023, With 10.328 Million Units Transfused CDC – National Blood Collection and Utilization Survey, 2023: Collection and Transfusion Volumes U.S. National Blood Collection and Utilization Survey – Reporting Facilities Rejected 72,139 Units Following Reactive Infectious-Disease Screening in 2023, Including 32,944 Associated With Hepatitis B Markers PubMed Central – National Blood Collection and Utilization Survey: Reactive Screening Results U.S. FDA / Federal Regulations – Blood Establishments Must Test Donations for HIV, Hepatitis B, and Hepatitis C Using Appropriately Licensed, Approved, or Cleared Screening Tests, Subject to Specified Exceptions eCFR – 21 CFR 610.40: Blood Donation Testing Requirements Abbott – Alinity s Is Designed for Blood and Plasma Screening, With Capacity for Up to 600 Tests per Hour and at Least Three Hours of Walk-Away Operation Abbott – Alinity s System: Blood and Plasma Screening Capacity and Workflow Bio-Rad Laboratories – IH-500 Automates Blood Grouping, Antibody Screening and Identification, Crossmatching, and Antibody Titration, With Laboratory Information System Connectivity FDA – Bio-Rad IH-500: Regulatory Summary and Immunohematology Applications bioMérieux – VIDAS HIV Panel Provides Fourth-Generation Immunoassays for Earlier Detection of Acute HIV Infection bioMérieux – VIDAS HIV Panel: Clinical HIV Screening and Diagnostic Assays Quest Diagnostics – Offers Complete Blood Count Testing for Clinical Screening of Anemia, Leukemia, and Inflammatory Processes Using Whole-Blood Specimens Quest Diagnostics – CBC Including Differential and Platelets: Test Code 6399 U.S. FDA – Abbott’s Alinity m HIV-1 Assay Supports Clinical HIV Management and Supplemental Confirmation, but Its Labeling Excludes Blood-Donor Screening FDA – Alinity m HIV-1: Intended Uses and Donor-Screening Limitation Roche – Launched cobas MPX-E on March 30, 2026, Combining HIV, Hepatitis B, Hepatitis C, and Hepatitis E Donor Screening in One Molecular Assay Roche – cobas MPX-E Four-in-One Donor Screening Assay Launch Grifols – Announced Procleix Plasmodium FDA Approval on April 16, 2026, Following the FDA’s March 16, 2026 Approval Letter Grifols – Procleix Plasmodium Assay for Malaria Screening of Blood Donors Abbott – Reported USD 9.341 Billion in Total Diagnostics Sales in 2024, Including USD 5.235 Billion From Core Laboratory Diagnostics Abbott – Full-Year 2024 Financial Results and Diagnostics Sales Breakdown Roche – Reported CHF 14.324 Billion in Diagnostics Division Sales in 2024 Roche – Full-Year 2024 Results: Diagnostics Division Performance Table of Contents - Global Blood Screening Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Technology, Product and Service, Screening Type, Application, Sample Type, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Technology, Product and Service, Screening Type, Application, Sample Type, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Technology, Product and Service, Screening Type, Application, Sample Type, and End User Investment Opportunities in the Blood Screening Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Nucleic Acid Testing, Multiplex Molecular Assays, Automated Immunoassays, Reagents and Consumables, Laboratory Software, and Transfusion Safety Screening Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Blood Screening in Infectious Disease Detection, Donor Eligibility Assessment, and Transfusion Safety Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Transfusion Safety Compliance Factors Role of Nucleic Acid Testing, Immunoassays, Automated Analyzers, and Multiplex Molecular Assays in Market Expansion Infectious Disease Surveillance, Laboratory Automation, Blood Traceability, and Diagnostic Quality Management Trends Global Blood Screening Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Technology: Nucleic Acid Testing (NAT) Immunoassay Technology Other Screening Technologies Market Analysis by Product and Service: Reagents and Consumables Instruments and Equipment Software and Services Market Analysis by Screening Type: Infectious Disease Screening Immunohematology Screening Other Blood Screening Market Analysis by Application: Blood Donor Screening Transfusion Safety Screening Clinical Diagnostic Screening Market Analysis by Sample Type: Whole Blood Plasma Serum Market Analysis by End User: Blood Banks and Blood Collection Centers Hospitals and Healthcare Institutions Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Blood Screening Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Technology, Product and Service, Screening Type, Application, Sample Type, and End User Country-Level Breakdown: United States Canada Mexico Europe Blood Screening Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Technology, Product and Service, Screening Type, Application, Sample Type, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Blood Screening Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Technology, Product and Service, Screening Type, Application, Sample Type, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Blood Screening Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Technology, Product and Service, Screening Type, Application, Sample Type, and End User Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Blood Screening Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Technology, Product and Service, Screening Type, Application, Sample Type, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Abbott Laboratories F. Hoffmann-La Roche Ltd. Grifols, S.A. Bio-Rad Laboratories, Inc. bioMérieux SA Siemens Healthineers AG Thermo Fisher Scientific Inc. Danaher Corporation Ortho Clinical Diagnostics Grifols Diagnostic Solutions Werfen QuidelOrtho Corporation Quest Diagnostics Competitive Landscape and Strategic Insights Benchmarking Based on Molecular Testing Capabilities, Assay Portfolios, Instrument Automation, Screening Throughput, and Regional Presence Supplier Qualification and Diagnostic Quality Compliance Analysis Nucleic Acid Testing and Multiplex Assay Positioning Infectious Disease Screening and Immunohematology Competitiveness Reagent Supply, Laboratory Software, and Automated Workflow Integration Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Technology, Product and Service, Screening Type, Application, Sample Type, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Regulatory Compliance and Blood Screening Safety Analysis Technology Adoption Trends Across Nucleic Acid Testing, Immunoassays, Automated Instruments, Reagents and Consumables, and Laboratory Software List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Technology, Product and Service, Screening Type, Application, Sample Type, and End User (2025 vs. 2032) Global Blood Screening Ecosystem and Value Chain Analysis